Literature DB >> 8272191

delta-Aminolevulinic acid effects on neuronal and glial tumor cell lines.

L Helson1, S Braverman, J Mangiardi.   

Abstract

Acute intermittent porphyria (AIP) or precursor syndrome is a well described neuropathic clinical entity with incompletely known etiology. The most prominent biological abnormalities associated with this syndrome are elevations in serum and hepatic delta-aminolevulinic acid (ALA) and porphobilinogen (PBG). We determined the impact of ALA and PBG on human neuroblastoma and glioblastoma tumor cell survival as measured by the MTT assay. ALA proved to be cytotoxic in neuroblastoma cells, while PBG lacked cytotoxic effects. This cytotoxic effect of ALA could be enhanced by deferoxamine and diminished by heme, presumably through modulation of ALA synthesis. In conclusion, ALA excess may prove to be associated with the development of neuropathy in AIP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8272191     DOI: 10.1007/bf00975044

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  25 in total

1.  ACUTE INTERMITTENT PORPHYRIA: THE FIRST "OVERPRODUCTION DISEASE" LOCALIZED TO A SPECIFIC ENZYME.

Authors:  D P TSCHUDY; M G PERLROTH; H S MARVER; A COLLINS; G HUNTER; M RECHCIGL
Journal:  Proc Natl Acad Sci U S A       Date:  1965-04       Impact factor: 11.205

2.  ON THE NATURE OF THE PERIPHERAL NERVE LESIONS ASSOCIATED WITH ACUTE INTERMITTENT PORPHYRIA.

Authors:  J B CAVANAGH; R S MELLICK
Journal:  J Neurol Neurosurg Psychiatry       Date:  1965-08       Impact factor: 10.154

3.  Porphobilinogen and delta-amino levulinic acid in acute porphyria.

Authors:  S GRANICK; H G VANDEN SCHRIECK
Journal:  Proc Soc Exp Biol Med       Date:  1955-02

4.  Abnormal iron and water metabolism in acute intermittent porphyria with new morphologic findings.

Authors:  J A Stein; F D Curl; M Valsamis; D P Tschudy
Journal:  Am J Med       Date:  1972-12       Impact factor: 4.965

Review 5.  Genetic, metabolic, and biochemical aspects of the porphyrias.

Authors:  S Sassa; A Kappas
Journal:  Adv Hum Genet       Date:  1981

6.  Effects of delta-aminolaevulinic acid, porphobilinogen and structurally related amino acids on 2-deoxy-glucose uptake in cultured neurons.

Authors:  V A Russell; M C Lamm; J J Taljaard
Journal:  Neurochem Res       Date:  1982-08       Impact factor: 3.996

7.  Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines.

Authors:  L V Rubinstein; R H Shoemaker; K D Paull; R M Simon; S Tosini; P Skehan; D A Scudiero; A Monks; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

8.  Heme biosynthesis in intermittent acute prophyria: decreased hepatic conversion of porphobilinogen to porphyrins and increased delta aminolevulinic acid synthetase activity.

Authors:  L J Strand; B F Felsher; A G Redeker; H S Marver
Journal:  Proc Natl Acad Sci U S A       Date:  1970-11       Impact factor: 11.205

9.  Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusions of hematin.

Authors:  H L Bonkowsky; D P Tschudy; A Collins; J Doherty; I Bossenmaier; R Cardinal; C J Watson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-11       Impact factor: 11.205

Review 10.  The porphyrias.

Authors:  J R Bloomer; H L Bonkovsky
Journal:  Dis Mon       Date:  1989-01       Impact factor: 3.800

View more
  2 in total

1.  Increased delta aminolevulinic acid and decreased pineal melatonin production. A common event in acute porphyria studies in the rat.

Authors:  H Puy; J C Deybach; A Bogdan; J Callebert; M Baumgartner; P Voisin; Y Nordmann; Y Touitou
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

2.  Delta-aminolevulinic acid cytotoxic effects on human hepatocarcinoma cell lines.

Authors:  Adriana De Siervi; Elba S Vazquez; Carolina Rezaval; María V Rossetti; Alcira M del Batlle
Journal:  BMC Cancer       Date:  2002-03-22       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.